UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (6), p.1517-1527

2016

Volltextzugriff (PDF)

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Molecular cancer therapeutics, 2015-09, Vol.14 (9), p.2060-2071

2015

Volltextzugriff (PDF)

Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment

Nanomedicine, 2019-04, Vol.17, p.71-81

2019

Volltextzugriff (PDF)

Spindle Checkpoint Proteins and Chromosome-Microtubule Attachment in Budding Yeast

The Journal of cell biology, 2004-02, Vol.164 (4), p.535-546

2004

Volltextzugriff (PDF)

Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors

Molecular cancer therapeutics, 2022-07, Vol.21 (7), p.1047-1059

2022

Volltextzugriff (PDF)

Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect

Molecular cancer therapeutics, 2013-09, Vol.12 (9), p.1816-1828

2013

Volltextzugriff (PDF)

Molecular Analysis of Kinetochore-Microtubule Attachment in Budding Yeast

Cell, 2001-07, Vol.106 (2), p.195-206

2001

Volltextzugriff (PDF)

Abstract 1533: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1533-1533

2019

Volltextzugriff (PDF)

Binding of the essential Saccharomyces cerevisiae kinetochore protein Ndc10p to CDEII

Molecular biology of the cell, 2003-11, Vol.14 (11), p.4557-4568

2003

Volltextzugriff (PDF)

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy

Molecular cancer therapeutics, 2021-01, Vol.20 (1), p.203-212

2021

Volltextzugriff (PDF)

Probing the architecture of a simple kinetochore using DNA-protein crosslinking

The Journal of cell biology, 1997-12, Vol.139 (6), p.1383-1396

1997

Volltextzugriff (PDF)

Abstract 1841: IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1841-1841

2021

Volltextzugriff (PDF)

Abstract 213: Development of a probody-drug conjugate targeting EpCAM for the treatment of solid tumors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.213-213

2019

Volltextzugriff (PDF)

Abstract 215: Generation of site-specific DARPin® drug conjugates using EGFR as a model system

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.215-215

2019

Volltextzugriff (PDF)

Abstract 4134: MM-302 is more effective than PEGylated liposomal doxorubicin (PLD) at reducing pulmonary metastatic burden in breast cancer models expressing intermediate levels of HER2

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4134-4134

2015

Volltextzugriff (PDF)

Abstract P6-11-05: Tumor priming with cyclophosphamide for enhanced tumor delivery, penetration and anti-tumor activity of MM-302, HER2-targeted liposomal doxorubicin

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P6-P6-11-05

2015

Volltextzugriff (PDF)

Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-061-LB-061

2016

Volltextzugriff (PDF)

Elevated GM-CSF and IL-1β levels compromise the ability of p38 MAPK inhibitors to modulate TNFα levels in the human monocytic/macrophage U937 cell line

Molecular bioSystems, 2010-01, Vol.6 (10), p.1956

2010

Volltextzugriff (PDF)

Elevated GM-CSF and IL-1β levels compromise the ability of p38 MAPK inhibitors to modulate TNFα levels in the human monocytic/macrophage U937 cell lineElectronic supplementary information (ESI) available: 6 Supplementary Figures, 3 datasets used to generate figures in the manuscript and supplementary methods. See DOI: 10.1039/c002848g

2010-10

Volltextzugriff (PDF)

Binding of the Essential Saccharomyces cerevisiaeKinetochore Protein Ndc10p to CDEII

Molecular biology of the cell, 2003-11, Vol.14 (11), p.4557-4568

2003

Volltextzugriff (PDF)

Elevated GM-CSF and IL-1beta levels compromise the ability of p38 MAPK inhibitors to modulate TNFalpha levels in the human monocytic/macrophage U937 cell line

Molecular bioSystems, 2010-10, Vol.6 (10), p.1956-1972

2010

Volltextzugriff (PDF)

High‐Throughput Protein‐Based Technologies and Computational Models for Drug Development, Efficacy, and Toxicity

Drug Efficacy, Safety, and Biologics Discovery, 2008, p.29-52

2008

Volltextzugriff (PDF)

Molecular architecture of the Saccharomyces cerevisiae kinetochore

Espelin, Christopher W

2004

Volltextzugriff (PDF)

Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools

1. Aufl., 2009

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(23)

Publikationsform

Sprache

Englisch
(24)
Japanisch
(4)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Cancer Research
(8)
Molecular Cancer Therapeutics
(4)
Molecular Biology Of The Cell
(2)
Molecular Biosystems
(2)
The Journal Of Cell Biology
(2)
The journal Of Cell Biology/the journal Of Cell Biology
(2)
Cell
(1)
Nanomedicine
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment

Spindle Checkpoint Proteins and Chromosome-Microtubule Attachment in Budding Yeast

Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors

Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect

Molecular Analysis of Kinetochore-Microtubule Attachment in Budding Yeast

Abstract 1533: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity

Binding of the essential Saccharomyces cerevisiae kinetochore protein Ndc10p to CDEII

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy

Probing the architecture of a simple kinetochore using DNA-protein crosslinking

Abstract 1841: IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models

Abstract 213: Development of a probody-drug conjugate targeting EpCAM for the treatment of solid tumors

Abstract 215: Generation of site-specific DARPin® drug conjugates using EGFR as a model system

Abstract 4134: MM-302 is more effective than PEGylated liposomal doxorubicin (PLD) at reducing pulmonary metastatic burden in breast cancer models expressing intermediate levels of HER2

Abstract P6-11-05: Tumor priming with cyclophosphamide for enhanced tumor delivery, penetration and anti-tumor activity of MM-302, HER2-targeted liposomal doxorubicin

Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo

Elevated GM-CSF and IL-1β levels compromise the ability of p38 MAPK inhibitors to modulate TNFα levels in the human monocytic/macrophage U937 cell line

Binding of the Essential Saccharomyces cerevisiaeKinetochore Protein Ndc10p to CDEII

Elevated GM-CSF and IL-1beta levels compromise the ability of p38 MAPK inhibitors to modulate TNFalpha levels in the human monocytic/macrophage U937 cell line

High‐Throughput Protein‐Based Technologies and Computational Models for Drug Development, Efficacy, and Toxicity

Molecular architecture of the Saccharomyces cerevisiae kinetochore

Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools

Suchergebnisse filtern